IFNAR2.1 short isoform has a truncated cytoplasmic tail of 67 residues, and is partially impaired in the signalling response [11] [12] [13] or incapable of complete signalling. 14 IFNAR2.3, lacking both the transmembrane and intracytoplasmic domains, is a soluble receptor isoform that has been found in different body fluids. 1,15 Depending on its relative concentration, the stability of its binding with the ligand and the rate of discharge, it may be regarded either as a competitive antagonist, acting as a molecular decoy, or, indirectly, as an agonist, as it protects bound IFN-β from degradation and prolongs its half-life. 16 The process of receptor activation involves the initial binding of type I IFNs to the IFNAR2 subunit 17 followed by the recruitment of the IFNAR1 subunit, with subsequent commencement of a signalling cascade 18 that leads to catalytic activation of associated tyrosine kinase 2 (Tyk2) and Janus tyrosine kinase 1 (Jak1), which in turn phosphorylate signal transducer and activator of transcription (STAT)-1 and STAT-2 (although activation of STAT-3, STAT-4, STAT-5 and STAT-6 has also been reported). [19] [20] [21] [22] All of these phenomena ultimately activate the IFN-stimulated response elements (ISRE) of the gene promoter, 23 which in turn regulate the transcription of the several genes responsible for the IFN-mediated effects.
Type I Interferons and Their Receptor
Human interferons (IFNs), first recognised for their potent antiviral activity 50 years ago, are a group of naturally occurring cytokines with important immunomodulatory, antiviral, antiangiogenic, antiproliferative and antitumour activities. 1 which are co-produced with IFN-β. 1 As found for most cytokines and growth factors, the actions of IFNs are mediated by an interaction with specific cell surface receptors. All of the type I IFNs share the same receptor complex, whereas type II IFN binds to a distinct receptor, as do the interferon-like cytokines IL-28A, IL-28B and IL-29. 3 The receptor complex for the type I IFNs consists of two chains, IFNAR1 and IFNAR2, 4, 5 whose genes are clustered on chromosome 21.
Two splice variants of IFNAR1 have been identified in cell lines, 6-8 but one is probably an artefact or an aberrant transcript found only in particular tumour cell lines. 9 In contrast, IFNAR2 is expressed in vivo in three different isoforms, which are generated by alternative splicing, exon skipping and differential usage of polyadenylation sites and differ in the length of the carboxyterminal tail and in the signalling capacity. 10 IFNAR2.2 full-length is the functional isoform, and is made up of 487 amino acids, 251 of which lie in the cytoplasmic portion. 11, 12 IFNAR2.1 short isoform has a truncated cytoplasmic tail of 67 residues, and is partially impaired in the signalling response [11] [12] [13] or incapable of complete signalling. 14 IFNAR2.3, lacking both the transmembrane and intracytoplasmic domains, is a soluble receptor isoform that has been found in different body fluids. 1, 15 Depending on its relative concentration, the stability of its binding with the ligand and the rate of discharge, it may be regarded either as a competitive antagonist, acting as a molecular decoy, or, indirectly, as an agonist, as it protects bound IFN-β from degradation and prolongs its half-life. 16 The process of receptor activation involves the initial binding of type I IFNs to the IFNAR2 subunit 17 followed by the recruitment of the IFNAR1 subunit, with subsequent commencement of a signalling cascade 18 that leads to catalytic activation of associated tyrosine kinase 2 (Tyk2) and Janus tyrosine kinase 1 (Jak1), which in turn phosphorylate signal transducer and activator of transcription (STAT)-1 and STAT-2 (although activation of STAT-3, STAT-4, STAT-5 and STAT-6 has also been reported). [19] [20] [21] [22] All of these phenomena ultimately activate the IFN-stimulated response elements (ISRE) of the gene promoter, 23 which in turn regulate the transcription of the several genes responsible for the IFN-mediated effects.
Interferon-β Treatment in Multiple Sclerosis
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system characterised by bouts of neurological symptoms (or relapses) and increasing disability. Although this disease was first described in the 1800s, 24 Luisa Imberti works in the Biotechnology Laboratory at Civic Hospital in Brescia, Italy, where she is Chair of the Allergy Diagnostic Service. Her main focus is on translational research, and she has contributed to advances in the biology and management of human primary and secondary (HIV) immunodeficiencies. Lately, her research group has been focusing on a multidisciplinary approach to addressing diagnostically relevant aspects of multiple sclerosis, in particular through the development of laboratory assays that allow more targeted interventions with patients, as well as benefits and costs containment. Dr Imberti received her MD from the University of Milan, and then undertook extensive training in tumour immunology in the US. considered an appropriate test to determine IFN-β bioavailability. [27] [28] [29] [30] However, some patients are unresponsive to treatment even in the absence of anti-IFN-β antibodies, 31 and therefore other reasons for lack of therapy efficacy still have to be identified.
Involvement of IFNAR in Interferon-β Activity
It has been proposed that the biological response to IFN-β could be affected not only by the presence of BAb or NAb, but also by other competing serum factors, 32,33 such as soluble IFNAR. 34 Furthermore, as a body of arguments suggests that the differential affinities for IFNARs govern the diverse biological activities among members of type I IFN families sharing the same receptor, 17, 18 it is also likely that differences in the amount of IFN-β and IFNAR binding may account for the differential therapeutic activity of the cytokine in different patients.
Finally, the cell surface concentration of IFNAR and lateral organisation of its two chains into microdomains might be other important cellular parameters that shape responsiveness to IFNs. 35 For example, the autocrine production of IFN-β from LPS-and poly I:C-matured dendritic cells can induce a marked decline in the level of the two IFNAR subunits, 35 and a modulation in receptor expression has been observed in the course of therapy with IFN-α in both HCV and chronic myelogenous leukaemia patients. 36, 37 If we consider the rather low number of IFNAR molecules on the cell surface, 12 especially on lymphocytes, 38 the three IFNAR2 isoforms is now available. 40 Using this method we have previously demonstrated that IFNAR1 and total IFNAR2 subunits are both expressed at high levels, and that IFNAR2.2 is significantly the most represented isoform, while IFNAR2.3 is found, on average, at barely detectable levels. However, the distribution of IFNAR2.3 isoform values is rather wide, indicating that it is possible to find higher levels of soluble receptor in the sera of a few samples. 40 We then used this laboratory test to quantify mRNA expression for all IFNAR components in a group of long-term IFN-β-treated MS patients selected among those undergoing routine MxA determination in our laboratory. Their IFNAR mRNA levels were compared with those of a control group and of therapy-naïve MS patients in order to ascertain receptor modulation during prolonged receptor stimulation by IFN-β. Our results indicated that the overall pattern of expression of the various subunits and isoforms in peripheral blood cells of MS patients is similar to that observed in healthy controls and in HIV patients. 42 
IFNAR1 Subunits in Interferon-β-treated Patients
We also found that naïve and IFN-β-treated MS patients showed a significantly decreased expression of mRNA for the IFNAR1 but not the IFNAR2 subunit in comparison with healthy controls (see Figure 1) .
Notably, the expression of IFNAR1 and IFNAR2 also appears to be At present, we cannot fully explain the reason for the decreased expression of IFNAR1 in our MS patients. Leyva et al. 45 showed a significant association between an IFNAR1 gene polymorphism and MS susceptibility, thus suggesting a possible role of IFNAR1 alteration in the development of MS. Since IFNAR1 has been described as a shortlived protein that is internalised and degraded rapidly via lysosomes upon ligand binding, 46 we hypothesise that the increase in IFNAR1
mRNA might serve as a mechanism for rapid counterbalancing of the receptor loss. The net effect of mRNA increment might be a restoration of IFNAR surface protein levels and, consequently, cell responsiveness to IFN-β, leading to MxA induction, at least in MxA-induced patients.
Recent functional studies in cell lines have directly related the binding affinity of IFN-β towards IFNAR1 with the specificity of its biological effects. 18 A possible higher efficiency of IFNAR1 restoration on the cell surface could be related to better IFN-β bioactivity.
Further studies are necessary to clarify whether the diminished IFNAR1 expression, restored only in the MxA-induced patients, can be somewhat correlated to the pathogenesis of the disease, or whether it is a mere consequence of chronic immune system activation or of its altered regulation. Whatever the situation, studies to detect these receptors may help in monitoring treatment response in MS patients. ■
